APTEEUS is a Biotech specialized in drug discovery and repositioning. Founded in 2013 by Dr Terence Beghyn and Professor Benoit Deprez, it brings together a team of researchers whose objective is to quickly respond to unmet medical needs. His area of expertise now covers a large number of diseases, including rare monogenic diseases. Whenever the cause of the disease can be measured in cultured patient cells, the team is committed to testing the effect of all existing drugs.
Concerned about reconciling the time of research with that of medicine, our first approach is based on the repositioning of molecules approved in humans. The team’s objectives are to respond quickly to the medical needs of patients by identifying candidates for repositioning, but also to identify new avenues of treatment for these diseases and less rare diseases. Motivated by science, medicine and pharmacy, we involve patients in finding their own treatment and systematically consider compassionate use of drugs before considering a new development.
evidenceFactory® is the miniaturized and automated cell screening technology that we have developed and offer in partnership with patient organizations, research teams and pharmaceutical companies. The use of primary cells directly from patients through the OPERANDO® project (NCT03763864) allows us to reproduce in vitro the physiopathology of the patient’s disease and to measure the effect of the molecules in our unique and proprietary TEE Library® collection.
With its PARTNERS, APTEEUS is fully committed to hereditary metabolic diseases and genodermatoses, but also considers other diseases.
The technological competitive advantages associated with APTEEUS’ development models are a complete break with the classic pharmaceutical R&D scheme and make APTEEUS a pioneer in Europe in providing economically viable solutions for the therapeutic management of rare monogenic diseases. APTEEUS aims for a rapid and significant social impact in the field of rare and orphan diseases.